Search
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. … [L4562] Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic
Categories: Antivirals used in combination for the treatment of HIV infectionsVestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalIn clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with … Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients.
Alternaria alternata
go.drugbank.com/drugs/DB10424ApprovedAlternaria alternata extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureRegdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Ublituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[L4799] Other biosimilars include adalimumab-fkjp - which was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935], adalimumab-aacf - which was approved in October … [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.
International brands: Humira PenProducts: AMGEVITA 40MG ILO I E PEN, AMGEVITA 40 MG ILO I E PENTeduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalFDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalcompared to standard VRd therapy. … In July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients.
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideDacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigationalAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). … Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.